Hey doc, are you sure this is CIDP?
By Jeffrey A. Allen MD,University of Minnesota It’s ok to ask the question. Whether you’ve had the diagnosis for a day or a decade its ok to ask. You should ask. Do my symptoms make sense? Are my test results what you would expect for CIDP? Have other explanations been explored? Should I get a…
A Clinical Study of Rozanolixizumab in Patients with CIDP
Clinical research studies are scientific evaluations in people, led by researchers and physicians. They can help advance the understanding of a disease and are the most important way for researchers to find out if potential new treatments are safe and effective. Studies like these are needed to be able to make new treatments available to…
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Published in The Lancet, May 7, 2019 Co-authored by Carina Bunschoten, Bart C Jacobs, Peter U K Van den Bergh, David R. Cornblath, Pieter A van Doorn
CIDP Disease Burden — Results of a US Nationwide Patient Survey
In 2017, a nationwide survey of US CIDP patients was conducted to assess the impact of disease-related disability and treatment on lifestyle and work activities. Approximately 3250 individuals aged ≥18 years, recruited by the GBS|CIDP Foundation and self-reported to have CIDP, were invited to complete an online survey; of these, 475 completed the survey and…
Research in CIDP: Are we making progress?
By Jeffrey A. Allen, MDMember, GBS|CIDP Foundation Global Medical Advisory Board CIDP as a named disease entity is now about 4 decades old. The laboratory data that helps define the disease, nerve conduction studies and in some cases cerebral spinal fluid and nerve biopsy, is even older; and the initial description of what has now…
CIDP Patient, Lynn Rogers, Running in Chicago Marathon!
For Rogers, this year has been filled with pain and triumph, a year of repetitive setbacks and remarkable progress. In August 2017, Rogers was paralyzed by a rare autoimmune condition, known as CIDP. Her first steps — at first with the assist of a harness — came a month later. Read more in Chicago Tribune….
Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP
David Saperstein, MD Co-Director GBS/CIDP Center of Excellence Phoenix Neurological Associates Phoenix, AZ Intravenous immunoglobulin (IVIg) is one of the main therapies used to treat CIDP. This therapy can be very effective but there are drawbacks. Some people experience headaches related to the intravenous infusions. Some people have difficulty with IV access. Also, the need…
FDA approves CSL Behring treatment for CIDP
The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) developed by CSL Behring. Lisa Butler, executive director of the GBS/CIDP Foundation International, said “The approval of Hizentra offers patients who were once burdened by traveling to the infusion center or hospital the flexibility to self-administer their treatment at…